Thomas Lynch, chairman of Amarin Corp. Plc has been appointed chief executive officer, replacing Rick Stewart who resigned from the company to pursue other business interests. The changes took effect in mid-December 2007.
At the same time, Alan Cooke, chief financial officer, took on the additional roles of president and chief operating officer. Mr Cooke is also a member of the company’s board of directors. Declan Doogan, head of research and development, has been named to the board, while Keith Wood was appointed head of research and development operations.
Mr Lynch joined Amarin in January 2000 as board chairman. Between 1993 and 2004, he was with Elan Corporation where he held a number of positions including chief financial officer and executive vice chairman.
Amarin develops products to treat central nervous system and cardiovascular diseases. It is headquartered in London and listed on NASDAQ in the US and on London’s Alternative Investment Market and Ireland’s IEX.
Source:
Amarin Corp press release, 19 December 2007
Copyright 2008 Evernow Publishing Ltd